Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks-Reference-Cited by-同舟云学术

Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks

Published:2017-07-19 Issue:8 Volume:71 Page:e12968
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Arrabal-Durán Paula¹,Rodríguez-González Carmen G¹^ORCID,Chamorro-de-Vega Esther¹,Gijón-Vidaurreta Paloma²,Herranz-Alonso Ana¹,Sanjurjo-Sáez María¹

Affiliation:

1. Pharmacy Department; Hospital General Universitario Gregorio Marañón; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM); Madrid Spain

2. Clinical Microbiology and Infectious Diseases Department; Hospital General Universitario Gregorio Marañón; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM); Madrid Spain

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ijcp.12968/fullpdf

Reference16 articles.

1. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel;Günthard;JAMA,2014

2. [Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2016)];AIDS Study Group (GESIDA) of the Spanish Society of Infectious Diseases, Clinical Microbiology, the National AIDS Plan;Enferm Infecc Microbiol Clin,2016

3. New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir;Patel;HIVAIDS (Auckl),2012

4. Triple-combination rilpivirine, emtricitabine, and tenofovir (CompleraTM/Eviplera™) in the treatment of HIV infection;Bernardini;Patient Prefer Adherence,2013

5. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants;Palella;AIDS,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical factors and outcomes associated with immune non-response among virally suppressed adults with HIV from Africa and the United States;Scientific Reports;2022-01-24

2. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis;International Journal of Antimicrobial Agents;2022-01

3. Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review;Pharmaceutics;2020-02-22

4. The role of rilpivirine in Southern Africa;Southern African Journal of HIV Medicine;2019-05-29

5. HIV-1 and Compromised Adult Neurogenesis: Emerging Evidence for a New Paradigm of HAND Persistence;Aids Reviews;2019-04-09